Cancer Treatment Reviews
Volume 30, Issue 8 , Pages 695-706 , December 2004

Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective

References 

  1. Jordan VC. Why tamoxifen? In: Jordan VC, editor. Tamoxifen: A guide for clinicians and patients. Huntington, NY; 1996. p. 15–23
  2. Howell A, Johnston SRD. Selective estrogen receptor modulators (SERMs). In:  Robertson JFR,  Nicholson RI,  Hayes DF editor. Endocrine therapy of breast cancer. London: Martin Dunitz; 2002;p. 45–62
  3. Sherwin BB. Estrogen and cognitive aging in women. Trends Pharmacol. Sci. 2002;23:527–534
  4. Cavailles V. Estrogens and receptors: an evolving concept. Climacteric. 2002;5(Suppl 2):20–26
  5. Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977;37:1901–1907
  6. Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD. Neoplasms of the breast. In:  Bast RC,  Kufe DW,  Pollock RE,  Weichselbaum RR,  Holland JF,  Frei III E editor. Cancer medicine. vol. 5:Hamilton: BC Decker; 2000;p. 1735–1822
  7. Beatson GT. On the treatment of inoperable cases of carcinogen of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:105–107
  8. Haddow A, Watkinson JM, Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ. 1944;2:393–398
  9. Bertelli G, Pronzato P, Amoroso D, et al.  Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res. Treat. 1988;12:307–310
  10. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 1996;14:78–84
  11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet1998;351:1451–67
  12. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994;86:527–537
  13. Robinson SP, Parker CJ, Jordan VC. Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res. Treat. 1990;16(Suppl):S9–S17
  14. Hasmann M, Rattel B, Loser R. Preclinical data for droloxifene. Cancer Lett. 1994;84:101–116
  15. Johnston SR, Riddler S, Haynes BP, et al.  The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br. J. Cancer. 1997;75:804–809
  16. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 1995;59:261–266
  17. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 1998;83:1158–1162
  18. Wiseman LR, Goa KL. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs. 1997;54:141–160
  19. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer – a double-blind cross-over trial. Breast Cancer Res. Treat. 1993;25:57–63
  20. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 1993;11:345–350
  21. Pyrhonen S, Valavaara R, Vuorinen J, Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res. Treat. 1994;29:223–228
  22. Pyrhonen S, Valavaara R, Modig H, et al.  Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the `nordic' phase III study. Br. J. Cancer. 1997;76:270–277
  23. Hayes DF, Van Zyl JA, Hacking A, et al.  Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 1995;13:2556–2566
  24. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res. Treat. 1997;45:251–262
  25. Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N. Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer – a comparative study by a double blind method with tamoxifen. Gan To Kagaku Ryoho. 1993;20:247–258
  26. Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res. Treat. 2001;65:119–124
  27. Pyrhonen S, Ellmen J, Vuorinen J, et al.  Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat. 1999;56:133–143
  28. Holli K, Valavaara R, Blanco G, et al.  Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J. Clin. Oncol. 2000;18:3487–3494
  29. Ke HZ, Chen HK, Qi H, et al.  Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone. 1995;17:491–496
  30. Loser R, Seibel K, Roos W, Eppenberger U. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. Eur. J. Cancer Clin. Oncol. 1985;21:985–990
  31. Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Droloxifene – a new anti-estrogen. A phase II study in advanced breast cancer. Acta Oncol. 1992;31:425–428
  32. Buzdar A, Hayes D, El-Khoudary A, et al.  Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res. Treat. 2002;73:161–175
  33. Nuttall ME, Bradbeer JN, Stroup GB, et al.  Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology. 1998;139:5224–5234
  34. Coombes RC, Haynes BP, Dowsett M, et al.  Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res. 1995;55:1070–1074
  35. Lee ES, Schafer JM, Yao K, et al.  Cross resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 2000;6:4893–4899
  36. Johnston SR, Gorbunova V, Lichinitser M, et al.  A multicentre double-blind randomised phase III trial of idoxifene versus tamoxifen as first-line endocrine therapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:29a; [abstract 113]
  37. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J. Pharmacol. Exp. Ther. 1998;287:1–7
  38. Munster PN, Buzdar A, Dhingra K, et al.  Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J. Clin. Oncol. 2001;19:2002–2009
  39. Buzdar AU, O'Shaughnessy J, Hudis C, et al.  Preliminary results of a randomized double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene in patients with locally advanced or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:45a; [abstract 178]
  40. Black LJ, Jones CD, Clark JH, Clemens JA. LY156758: a unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity and near-total estrogen antagonism in vivo. Breast Cancer Res. Treat. 1982;2:279; [abstract 12]
  41. Buzdar AU, Marcus C, Holmes F. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology. 1988;45:344–345
  42. Gradishar WJ, Glusman JE, Vogel C, et al.  Raloxifene HCI, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Cancer Res. Treat. 1997;46(1): [abstract 209]
  43. Delmas PD, Bjarnason NH, Mitlak BH, et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997;337:1641–1647
  44. Cauley JA, Norton L, Lippman ME, et al.  Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001;65:125–134
  45. Jubelirer SJ, Crowell EB. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia. W V Med. J. 2000;96:602–604
  46. Cotreau MM, Stonis L, Dykstra KH, et al.  Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. J. Clin. Pharmacol. 2002;42:157–165
  47. Lønning PE, Taylor PD, Anker G, et al.  High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 2001;67:111–116
  48. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res. Treat. 1999;54:117–122
  49. Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat. Rep. 1981;65:179–185
  50. Ingle JN, Ahmann DL, Green SJ, et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N. Engl. J. Med. 1981;304:16–21
  51. Heuson JC, Engelsman E, Blonk-Van Der Wijst J, et al.  Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an EORTC study. Br. Med. J. 1975;2:711–713
  52. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am. J. Clin. Oncol. 1985;8:128–133
  53. Stewart HJ, Forrest AP, Gunn JM, et al.  The tamoxifen trial – a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Eur. J. Cancer. 1980;(Suppl 1):83–88
  54. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873
  55. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br. J. Cancer. 2002;87:1354–1359
  56. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000;89:817–825
  57. Howell A, DeFriend DJ, Robertson JF, et al.  Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer. 1996;74:300–308
  58. Howell A, Robertson JFR, Quaresma Albano J, et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002;20:3396–3403
  59. Osborne CK, Pippen J, Jones SE, et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002;20:3386–3395
  60. Robertson JFR, Osborne CK, Howell A, et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229–238
  61. Robertson JFR, Howell A, Abram P, Lichinitser M, Elledge R. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann. Oncol. 2002;13(Suppl 5):46; [abstract 164O]
  62. Howell A, Robertson JFR. Sensitivity to endocrine therapy is maintained in both fulvestrant- and tamoxifen-treated postmenopausal women with advanced breast cancer. Ann. Oncol. 2002;13(Suppl 5):46; [abstract 173P]
  63. Nabholtz JM, Buzdar A, Pollak M, et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 2000;18:3758–3767
  64. Mouridsen H, Gershanovich M, Sun Y, et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001;19:2596–2606
  65. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–39
  66. Buzdar A. The ATAC (`Arimidex', tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res. Treat. 2003;77:295
  67. Dardes RC, O'Regan RM, Gajdos C, et al.  Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin. Cancer Res. 2002;8:1995–2001
  68. Yamamoto N, Wada O, Yanagisawa J. A novel antiestrogen, TAS-108 (SR 16234) shows full antagonist activity to ER alpha and beta with a unique mechanism. Eur. J. Cancer. 2002;39(Suppl 3):S96; [abstract 217]
  69. Johnston SR. Acquired tamoxifen resistance in human breast cancer – potential mechanisms and clinical implications. Anticancer Drugs. 1997;8:911–930

PII: S0305-7372(04)00076-3

doi: 10.1016/j.ctrv.2004.04.003

Cancer Treatment Reviews
Volume 30, Issue 8 , Pages 695-706 , December 2004

Article Tools

* Image Usage & Resolution